<DOC>
	<DOC>NCT01069120</DOC>
	<brief_summary>Safety and efficacy study of 25 and 50 mg doses of Proellex</brief_summary>
	<brief_title>Safety of 25 and 50 mg ProellexÂ® in the Treatment of Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>The study is intended to provide more abundant safety and efficacy data of both the 25 and 50 mg doses of Proellex than ZPU-301, ZPU-302, ZPU-303 and ZPU-304 alone.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>At least 1 uterine fibroid must be identifiable and measurable by Transvaginal Ultrasound (TVU) Subject has a menstrual cycle lasting from 20 to 40 days. Subject must have satisfactorily completed all study visits from the previous study in which she participated: ZPU301, ZPU302, ZPU303, or ZPU304 Subjects who have not participated in 1 of the previous Repros studies: ZPU301, ZPU302, ZPU303, or ZPU304. Subjects who met treatment stopping rules as per the DILI Guidance requirements while participating in ZPU301, ZPU302, ZPU303, or ZPU304</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine Fibroids</keyword>
</DOC>